Vergote I, Larsen R H, de Vos L, Nesland J M, Bruland O, Bjørgum J, Alstad J, Tropé C, Nustad K
Department of Gynecologic Oncology, Norwegian Radium Hospital, Oslo.
Gynecol Oncol. 1992 Dec;47(3):366-72. doi: 10.1016/0090-8258(92)90141-5.
alpha-Emitting radionuclides such as 211At have a number of physical characteristics which make them attractive for the treatment of micrometastases. 211At was bound to polymer microspheres and its efficacy was compared with the beta-emitting 32P and 90Y colloids for the treatment of intraperitoneally growing K13 hybridoma tumors in mice. Single graded doses of 0.1-2.5 MBq 211At microspheres injected intraperitoneally 24 hr after inoculation of the hybridoma cells improved survival and produced higher cure rates than 32P colloid, 90Y colloid, or no treatment. One of the most striking contrasts between 211At microspheres and 90Y or 32P colloids was the ability of relatively low doses 211At to affect cures. When comparing the groups with the highest survival rate for each radionuclide (0.1-1 MBq 211At, 2.5 MBq 90Y, and 2.5 MBq 32P), 211At treatment resulted in an improved survival over that with 32P therapy, but the difference was not significant between 211At and 90Y. Toxicity studies with 211At microspheres showed that dosages up to 17 MBq per mouse were not lethal. In conclusion, the present study suggests that the high-energy transfer and the short-range cytotoxicity of the alpha-emitter 211At might be of benefit for intracavitary radiotherapy.
发射α粒子的放射性核素,如砹-211,具有许多物理特性,使其在治疗微转移方面具有吸引力。将砹-211与聚合物微球结合,并将其疗效与发射β粒子的磷-32和钇-90胶体进行比较,用于治疗小鼠腹腔内生长的K13杂交瘤肿瘤。在接种杂交瘤细胞24小时后,腹腔注射单剂量分级为0.1 - 2.5兆贝可的砹-211微球,与磷-32胶体、钇-90胶体或不治疗相比,可提高生存率并产生更高的治愈率。砹-211微球与钇-90或磷-32胶体之间最显著的对比之一是相对低剂量的砹-211影响治愈的能力。当比较每种放射性核素生存率最高的组(0.1 - 1兆贝可的砹-211、2.5兆贝可的钇-90和2.5兆贝可的磷-32)时,砹-211治疗导致的生存率高于磷-32治疗,但砹-211与钇-90之间的差异不显著。对砹-211微球的毒性研究表明,每只小鼠剂量高达17兆贝可并不致命。总之,本研究表明,α发射体砹-211的高能量转移和短程细胞毒性可能有利于腔内放射治疗。